Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369882 | 1.00 | GBA1 (0.51) | GBA1BCHEMAOBS1PR5S1PR1 | |
| SCHEMBL3369886 | 1.00 | GBA1 (0.51) | GBA1BCHEMAOBS1PR5S1PR1 | |
| SCHEMBL2937649 | 0.90 | RORC (0.44) | GBA1BCHEMAOBS1PR5S1PR1 | |
| SCHEMBL2937648 | 0.90 | RORC (0.44) | GBA1BCHEMAOBS1PR5S1PR1 | |
| SCHEMBL28249935 | 0.79 | GBA1 (0.58) | GBA1S1PR5S1PR1TSHR | |
| SCHEMBL3371156 | 0.76 | GBA1 (0.56) | GBA1S1PR5S1PR1ALDH1A1 | |
| SCHEMBL13105230 | 0.76 | GBA1 (0.56) | GBA1S1PR5S1PR1ALDH1A1 | |
| SCHEMBL3371158 | 0.76 | GBA1 (0.56) | GBA1S1PR5S1PR1ALDH1A1 | |
| SCHEMBL1190716 | 0.76 | GBA1 (0.75) | GBA1S1PR5S1PR1 | |
| SCHEMBL742926 | 0.76 | GBA1 (0.75) | GBA1S1PR5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | GBA1 1341/4885BCHE 1374/4885MAOB 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.